TWD 179.0
(-1.65%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 563 Million TWD | 245.92% |
2022 | -385.82 Million TWD | -145.05% |
2021 | 856.39 Million TWD | 33.83% |
2020 | 639.93 Million TWD | 534.7% |
2019 | -147.21 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | 604.8 Million TWD | 7.42% |
2024 Q2 | 504.52 Million TWD | -16.58% |
2023 Q4 | 563 Million TWD | -27.57% |
2023 FY | 563 Million TWD | 245.92% |
2023 Q1 | 77.84 Million TWD | 118.08% |
2023 Q3 | 777.26 Million TWD | 137.24% |
2023 Q2 | 327.63 Million TWD | 320.9% |
2022 Q4 | -430.54 Million TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 227.48 Million TWD | -147.49% |
Maxigen Biotech Inc. | -431.03 Million TWD | 230.619% |
SciVision Biotech Inc. | -163.18 Million TWD | 445.006% |
Bionime Corporation | 2.42 Billion TWD | 76.787% |
Pegavision Corporation | 63.52 Million TWD | -786.306% |